论文部分内容阅读
目的:MiR-378a-5p是一种被认为在多种肿瘤发生过程中具有抑制肿瘤生长的微小RNA。然而miR-378a-5p在鼻咽癌中的作用尚未见报道。因此,本文旨在通过临床样本的miRNA表达谱分析以及细胞学实验从而揭示miR-378a-5p在鼻咽癌肿瘤发生过程中的作用。方法与结果:我们通过生物信息学的方法获取了鼻咽癌临床样本中miR-378a-5p的表达信息并通过与正常组织的对比发现miR-378a-5p在鼻咽癌肿瘤组织中表达水平显著降低(P<0.01)。其次,我们发现高表达miR-378a-5p的鼻咽癌CNE-1细胞增殖速度显著较对照组降低(约40%~50%)。克隆形成实验证实了瞬时转染miR-378a-5p的鼻咽癌CNE-1细胞的克隆形成数量显著减弱。我们通过将稳定表达miR-378a-5p的CNE-1细胞注射到裸鼠体内形成移植瘤并记录肿瘤生长曲线,结果显示miR-378a-5p高表达组的裸鼠移植瘤体积明显较对照组小约50%,肿瘤重量显著降低(对照组0.33 g,处理组0.15 g)。结论:本研究通过对临床样本的分析以及在细胞和动物水平的实验验证揭示了miR-378a-5p具有抑制鼻咽癌肿瘤细胞增殖和肿瘤生长的作用。
PURPOSE: MiR-378a-5p is a microRNA that is thought to inhibit tumor growth during various tumorigenesis. However, the role of miR-378a-5p in NPC has not been reported yet. Therefore, this paper aims to reveal the role of miR-378a-5p in the carcinogenesis of nasopharyngeal carcinoma by miRNA expression profiling and cytology experiments in clinical samples. Methods and Results: We obtained the expression information of miR-378a-5p in clinical samples of nasopharyngeal carcinoma by bioinformatics methods and compared the expression of miR-378a-5p in nasopharyngeal carcinoma tissue with normal tissues Decreased (P <0.01). Second, we found that CNE-1 cells with miR-378a-5p overexpression significantly reduced the proliferation rate (about 40% -50%) compared with the control group. Clonogenic assays confirmed that the number of clonogenic CNE-1 cells transiently transfected with miR-378a-5p was significantly reduced. We injected CNE-1 cells stably expressing miR-378a-5p into nude mice to form xenografts and recorded tumor growth curves. The results showed that the tumor volume of nude mice in miR-378a-5p overexpression group was significantly smaller than that in control group About 50%, tumor weight was significantly reduced (control group 0.33 g, treatment group 0.15 g). CONCLUSIONS: The present study revealed that miR-378a-5p can inhibit the proliferation and tumor growth of nasopharyngeal carcinoma cells through the analysis of clinical samples and experimental verification at the cell and animal level.